Moderna (MRNA) Share-based Compensation (2018 - 2026)

Moderna (MRNA) has reported Share-based Compensation for 9 consecutive years, with $120.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 7.69% year-over-year to $120.0 million in Q2 2026; TTM through Jun 2026 was $462.0 million, a 0.22% change from a year earlier, with the FY2025 full-year figure at $483.0 million, up 12.59% from the prior year.
• Share-based Compensation was $120.0 million for Q2 2026 at Moderna, up from $104.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $130.0 million in Q2 2025 and troughed at $44.0 million in Q1 2022.
• A 5-year average of $92.6 million and a median of $102.5 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 75.0% in 2022 and decreased 9.57% in 2026, its largest moves.
• Over 5 years, Share-based Compensation stood at $62.0 million in 2022, then gained by 27.42% to $79.0 million in 2023, then surged by 31.65% to $104.0 million in 2024, then increased by 8.65% to $113.0 million in 2025, then climbed by 6.19% to $120.0 million in 2026.
• The last three Share-based Compensation figures came in at $120.0 million (Q2 2026), $104.0 million (Q1 2026), and $113.0 million (Q4 2025), per Business Quant data.